연구동향 분석

ORIGINAL ARTICLE : Clinical impact of routine follow-up coronary angiography after second- or third-generation drug-eluting stent insertion in clinically stable patients

( Seong Hoon Choi ) ( Hee Sun Mun ) ( Min Kyung Kang ) ( Jung Rae Cho ) ( Seong Woo Han ) ( Nam Ho Lee ) 2015년

논문상세정보
인용/피인용
' ORIGINAL ARTICLE : Clinical impact of routine follow-up coronary angiography after second- or third-generation drug-eluting stent insertion in clinically stable patients' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • coronary angiography
  • drug-elutingstents
  • follow-up
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
56 0

0.0%

' ORIGINAL ARTICLE : Clinical impact of routine follow-up coronary angiography after second- or third-generation drug-eluting stent insertion in clinically stable patients' 의 참고문헌

  • Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study
    Raber L Circulation 125 : 1110 ~ 1121 [2012]
  • Thijs Plokker HW. Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study
    ten Berg JM J Am Coll Cardiol 38 : 1061 ~ 1069 [2001]
  • The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention
    Kip KE J Am Coll Cardiol 51 : 701 ~ 707 [2008]
  • The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of “oculostenotic”reintervention in patients with intermediate lesions
    Uchida T JACC Cardiovasc Interv 3 : 403 ~ 411 [2010]
  • Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation:a randomised, multicentre, open-label, controlled trial
    Camenzind E Lancet 380 : 1396 ~ 1405 [2012]
  • Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial
    Stone GW J Am Coll Cardiol 56 : 1597 ~ 1604 [2010]
  • Second-generation drug-eluting stents and the continuous need for rapidly available real-world data
    Mukherjee D JACC Cardiovasc Interv 2 : 1236 ~ 1239 [2009]
  • Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Stone GW N Engl J Med 356 : 998 ~ 1008 [2007]
  • Routine coronary angiographic follow-up and subsequent revascularization in patients with acute myocardial infarction
    Shimada K Heart Vessels 23 : 383 ~ 389 [2008]
  • Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement
    Schuhlen H Am Heart J 147 : 317 ~ 322 [2004]
  • Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial
    Stone GW Circulation 119 : 680 ~ 686 [2009]
  • Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischemic heart disease
    Topol EJ Circulation 92 : 2333 ~ 2342 [1995]
  • Long-term clinical outcomes with the next-generation resolute stent system: a report of the two-year follow-up from the RESOLUTE clinical trial
    Meredith IT EuroIntervention 5 : 692 ~ 697 [2010]
  • Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS):4 year follow-up of a randomised non-inferiority trial
    Stefanini GG Lancet 378 : 1940 ~ 1948 [2011]
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents:5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the medtronic endeavor Drug [ABT-578]eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions)
    Kandzari DE JACC Cardiovasc Interv 4 : 543 ~ 550 [2011]
  • Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial
    Pinto DS J Am Coll Cardiol 48 : 32 ~ 36 [2006]
  • Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years
    Lansky AJ Am J Cardiol 110 : 21 ~ 29 [2012]
  • Impact of routine angiographic follow-up after angioplasty
    Rupprecht HJ Am Heart J 136 (4 Pt 1) : 613 ~ 619 [1998]
  • Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators
    Ruygrok PN J Am Coll Cardiol 34 : 1507 ~ 1511 [1999]
  • Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial
    Stone GW JAMA 299 : 1903 ~ 1913 [2008]
  • Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial
    Meredith IT JACC Cardiovasc Interv 2 : 977 ~ 985 [2009]
  • Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials
    Stefanini GG Eur Heart J 33 : 1214 ~ 1222 [2012]
  • Aspirin versus clopidogrel following dual antiplatelet therapy on the era of drug eluting stents
    Park TK J Am Coll Cardiol 63 (12 Suppl) : A1612 ~ [2014]